The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors
Journal of Alzheimer’s Disease · 2024
DOI: 10.1177/13872877241289602 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Donald E Moss und 1 weiteren Autor:innen. Beteiligte Einrichtung: Professor Emeritus, University of Texas at El Paso, El Paso, TX, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Basal Forebrain, Cholinesterase Inhibitors, tau Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
A conundrum in Alzheimer's disease (AD) is why the long-term use of acetylcholinesterase (AChE) inhibitors, intended for treatment of dementia, results in slowing neurodegeneration in the cholinergic basal forebrain, hippocampus, and cortex. The phospho-tau cascade hypothesis presented here attempts to answer that question by unifying three hallmark features of AD into a specific sequence of events. It is proposed that the hyperphosphorylation of tau protein leads to the AD-associated deficit of nerve growth factor (NGF), then to atrophy of the cholinergic basal forebrain and dementia. Because the release of pro-nerve growth factor (pro-NGF) is activity-dependent and is controlled by basal forebrain projections to the hippocampus and cortex, our hypothesis is that AChE inhibitors act by increasing acetylcholine-dependent pro-NGF release and, thus, augmenting the availability of mature NGF and improving basal forebrain survival. If correct, improved central nervous system-selective AChE inhibitor therapy started prophylactically, before AD-associated basal forebrain atrophy and cognitive impairment onset, has the potential to delay not only the onset of dementia but also its rate of advancement. The phospho-tau hypothesis thus suggests that preventing hyperphosphorylation of tau protein, early should be a high priority as a strategy to help reduce dementia and its associated widespread social and economic suffering.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Professor Emeritus, University of Texas at El Paso, El Paso, TX, USA.
- CEO, R&R Perez LLC, El Paso, TX, USA.
ORCID-Profile: Donald E Moss
Zitieren
APA
Moss, D. E., & Perez, R. G. (2024). The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241289602
Vancouver
Moss DE, Perez RG. The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241289602
BibTeX
@article{Moss2024,
author = {Moss, Donald E and Perez, Ruth G},
title = {The phospho-tau cascade, basal forebrain neurodegeneration, and dementia in Alzheimer's disease: Anti-neurodegenerative benefits of acetylcholinesterase inhibitors},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.1177/13872877241289602}
}
EUVIMED